REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced that Curran M. Simpson, Chief Operations and Technology Officer, will present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on April 27, 2021, at 3:15 p.m. ET. The event will be held virtually. A webcast of the presentation will be available in the Investors section of REGENXBIO's website and can be accessed at www.regenxbio.com. An archived replay will be accessible for 30 days post-event.

REGENXBIO is focused on advancing gene therapy using its NAV® Technology Platform.

ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M. Simpson, Chief Operations and Technology Officer, will present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 3:15 p.m. ET. The conference will be held in a virtual meeting format.

A webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the fireside chat.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com  

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-5th-annual-genetic-medicines-manufacturing-summit-301273377.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO present at the Chardan Genetic Medicines Manufacturing Summit?

REGENXBIO will present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on April 27, 2021, at 3:15 p.m. ET.

How can I access the webcast of REGENXBIO's presentation?

The webcast of REGENXBIO's presentation can be accessed at the Investors section of their website, www.regenxbio.com.

Is there a replay available for REGENXBIO's presentation?

Yes, an archived replay of REGENXBIO's presentation will be available for approximately 30 days after the event.

What technology platform does REGENXBIO utilize for gene therapy?

REGENXBIO utilizes its proprietary NAV® Technology Platform for gene therapy.

What is the focus of REGENXBIO as a biotechnology company?

REGENXBIO focuses on improving lives through the curative potential of gene therapy.